Abstract
Background There is a strong rationale for fixed-dosing of monoclonal antibodies in oncology. Although fixed-dosing of recently introduced monoclonal antibodies is well accepted, the rationale is also applicable for other monoclonal antibodies that already have been used for years, but are still body-size-based dosed in many hospitals. In the Netherlands Cancer Institute, Antoni van Leeuwenhoek (NKI-AVL), fixed-dosing has been implemented now for all monoclonal antibodies and, therefore, this site offers an ideal opportunity for a cost analysis study. Objective To investigate the financial impact of switching to fixed-dosing in the NKI-AVL. Setting The NKI-AVL. Method Information on the preparations of monoclonal antibodies was collected from August 2017 to February 2020. We compared the number of vials needed during preparation for fixed-dosing and body-size -based dosing strategies. The economic impact was calculated for 2 scenarios: scenario 1 assumed clustering of all preparations per day and scenario 2 assumed no clustering of preparations. Main outcome measure Number of saved vials and the correlating savings in health care costs. Results The implementation of fixed-dosing resulted in a substantial reduction in vials used for almost all monoclonal antibodies. The economic savings were calculated to be €0,8 and €3,1 million per year for scenario 1 and 2, respectively. Conclusion Fixed-dosing resulted in substantial savings in health care costs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22(10):1212–21.
Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49(9):1012–24.
European Medicines Agency. Keytruda Procedural steps taken and scientific information after the authorisation. EMA. 2020 June. Report No.: EMA/326531/2020. https://www.ema.europa.eu/en/documents/procedural-steps-after/keytruda-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. Accessed 27 July 2020.
European Medicines Agency.OPDIVO Procedural steps taken and scientific information after the authorisation. EMA. 2020 May. Report No.: EMA/233870/2020. https://www.ema.europa.eu/en/documents/procedural-steps-after/opdivo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. Accessed 27 July 2020.
Heinhuis KM, Beijnen JH, Hendrikx JJMA. Follow up survey for implementation of fixed-dosing of monoclonal antibodies. Int J Clin Pharm. 2020;42(1):3–6.
Zorginstituut Nederland [Internet]. Horizonscan Geneesmiddelen > Geneesmiddelen > Oncologie en Hematologie. 2019. https://www.horizonscangeneesmiddelen.nl/geneesmiddelen. Accessed 27 July 2020.
Nederlandse Vereniging voor Medische Oncologie [Internet]. Oncologische middelen. 2020. [cited 2020 July 27] Available from: https://www.nvmo.org/bom-type/bom/?order=medicine.
Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10(2):183–203.
Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11(2):219–38.
Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs. 2020;12(1):1703531.
Ogungbenro K, Patel A, Duncombe R, Nuttall R, Clark J, Lorigan P. Dose rationalization of pembrolizumab and nivolumab using pharmacokinetic modeling and simulation and cost analysis. Clin Pharmacol Ther. 2018;103(4):582–90.
Mukherjee S, Ibrahimi S, Machiorlatti M, Roman D, Saleem R, Hassan A, et al. Personalized dosing versus fixed dosing of immune checkpoint inhibitors. Am J Ther. 2018;25(6):e767–e768768.
Hall E, Zhang J, Kim EJ, Hwang G, Chu G, Bhatia S, et al. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Med. 2020;9(6):2106–12.
Bayle A, Besse B, Annereau M, Bonastre J. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact? Eur J Cancer. 2019;113:28–31.
Goldstein DA, Gordon N, Davidescu M, Leshno M, Steuer CE, Patel N, et al. A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non–small cell lung cancer. J Natl Cancer Inst. 2017;109(11):10.
R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. URL https://www.R-project.org/.
Zorginstituut Nederland [Internet]. Medicijnkosten. 2019. [cited 2020 July 27]. Available from: https://www.medicijnkosten.nl/.
Fryar CD, Kruszon-Moran D, Gu Q, Ogden CL. Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999–2000 through 2015–2016. Natl Health Stat Report. 2018;122:1–16.
Acknowledgements
Not applicable.
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare that they have no conflicts of interest related to this study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Heinhuis, K.M., Barkman, H.J., Beijnen, J.H. et al. A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute. Int J Clin Pharm 43, 181–190 (2021). https://doi.org/10.1007/s11096-020-01131-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-020-01131-z